ANNETTE FLECKENSTEIN

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi request reprint Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity
    A E Fleckenstein
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Rm 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 406:1-13. 2000
  2. ncbi request reprint New insights into the mechanism of action of amphetamines
    Annette E Fleckenstein
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Annu Rev Pharmacol Toxicol 47:681-98. 2007
  3. pmc Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure
    Lisa M McFadden
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 340:295-303. 2012
  4. ncbi request reprint Impact of psychostimulants on vesicular monoamine transporter function
    Annette E Fleckenstein
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 479:283-9. 2003
  5. pmc 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse
    Gregory C Hadlock
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 339:530-6. 2011
  6. ncbi request reprint A single methamphetamine administration rapidly decreases vesicular dopamine uptake
    Jeffrey M Brown
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 302:497-501. 2002
  7. ncbi request reprint Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity
    Jannine G Truong
    University of Utah, Salt Lake City, 84112, USA
    J Pharmacol Exp Ther 314:1087-92. 2005
  8. ncbi request reprint Bupropion increases striatal vesicular monoamine transport
    Kristi S Rau
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Neuropharmacology 49:820-30. 2005
  9. ncbi request reprint Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Neurosci Methods 155:109-15. 2006
  10. ncbi request reprint Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake
    Kristi S Rau
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Rm 201, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 318:676-82. 2006

Research Grants

  1. K02 Application
    ANNETTE FLECKENSTEIN; Fiscal Year: 2007
  2. Psychostimulants and Monoamine Transporters
    ANNETTE FLECKENSTEIN; Fiscal Year: 2009
  3. DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINES
    ANNETTE FLECKENSTEIN; Fiscal Year: 2009
  4. Psychostimulants and Monoamine Transporters
    ANNETTE FLECKENSTEIN; Fiscal Year: 2010
  5. DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINES
    ANNETTE FLECKENSTEIN; Fiscal Year: 2007
  6. Psychostimulants and Monoamine Transporters
    ANNETTE FLECKENSTEIN; Fiscal Year: 2007
  7. DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINES
    ANNETTE FLECKENSTEIN; Fiscal Year: 2004
  8. DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINES
    ANNETTE FLECKENSTEIN; Fiscal Year: 2010

Collaborators

  • Glen Hanson
  • Lisa M McFadden
  • Evan L Riddle
  • Jeffrey M Brown
  • Jonathan P Danaceau
  • John Haycock
  • M A Elwan
  • F Ivy Carroll
  • Trent J Volz
  • Jannine G Truong
  • Kristi S Rau
  • Diana G Wilkins
  • Kamisha L Johnson-Davis
  • James W Gibb
  • Veronica Sandoval
  • Pei Wen Chu
  • Elisabeth Birdsall
  • Anthony J Baucum
  • Gregory C Hadlock
  • Sarah J Farnsworth
  • James A Riordan
  • Jarom E Hanson
  • Yvette V Ugarte
  • J Paul Hansen
  • Ryan R Metzger
  • Michael J Crosby
  • Katy M Webb
  • Amanda J Hoonakker
  • David M Andrenyak
  • Kevin M Conrad
  • Jonathan D Ellis
  • Scott C Allen
  • Christopher L German
  • Paula L Vieira-Brock
  • Cameron S Metcalf
  • Kristi S Seferian
  • Shane D Rowley
  • Jill L King
  • Rebecca Bitter
  • Brian P Adair
  • Jakub Baudys
  • Dennis J Crouch
  • Amy H Newman
  • Gary W Miller

Detail Information

Publications38

  1. ncbi request reprint Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity
    A E Fleckenstein
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Rm 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 406:1-13. 2000
    ..Hence, this review will describe recent ex vivo studies investigating the rapid and differential affects of several stimulants on both plasmalemmal and vesicular monoamine transporter function...
  2. ncbi request reprint New insights into the mechanism of action of amphetamines
    Annette E Fleckenstein
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Annu Rev Pharmacol Toxicol 47:681-98. 2007
    ..All of these mechanisms have potential implications for both amphetamine- and methamphetamine-induced neurotoxicity, as well as dopaminergic neurodegenerative diseases...
  3. pmc Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure
    Lisa M McFadden
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 340:295-303. 2012
    ..Taken together, these results may provide insight into the neurochemical deficits reported in human METH abusers...
  4. ncbi request reprint Impact of psychostimulants on vesicular monoamine transporter function
    Annette E Fleckenstein
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 479:283-9. 2003
    ..As described in this review, these studies not only provide insight into the pharmacological actions of stimulants, but also mechanisms underlying neurodegenerative disorders, including Parkinson's disease...
  5. pmc 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse
    Gregory C Hadlock
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 339:530-6. 2011
    ..These data demonstrate that mephedrone has a unique pharmacological profile with both abuse liability and neurotoxic potential...
  6. ncbi request reprint A single methamphetamine administration rapidly decreases vesicular dopamine uptake
    Jeffrey M Brown
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 302:497-501. 2002
    ..These studies provide further evidence that psychostimulants rapidly and differentially modify vesicular DA uptake. In addition, these studies demonstrate a complex role for D(2) DA receptors in altering vesicular DA transport...
  7. ncbi request reprint Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity
    Jannine G Truong
    University of Utah, Salt Lake City, 84112, USA
    J Pharmacol Exp Ther 314:1087-92. 2005
    ..Implications with regard to methamphetamine-induced dopaminergic deficits, as well as dopamine-associated neurodegenerative disorders such as Parkinson's disease, are discussed...
  8. ncbi request reprint Bupropion increases striatal vesicular monoamine transport
    Kristi S Rau
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Neuropharmacology 49:820-30. 2005
    ..The findings from this study demonstrate similarities and differences in the mechanism by which MPD and bupropion affect striatal dopaminergic nerve terminals...
  9. ncbi request reprint Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Neurosci Methods 155:109-15. 2006
    ....
  10. ncbi request reprint Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake
    Kristi S Rau
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Rm 201, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 318:676-82. 2006
    ..These findings suggest a link between METH-induced alterations in serotonergic hippocampal vesicular uptake and the persistent hippocampal serotonergic deficits induced by the stimulant...
  11. ncbi request reprint Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, 84112, USA
    Synapse 60:474-7. 2006
    ..PND 88-92 rats. However, decreased VMAT-2 density in PND 38-42 rats reduces V(max), which in turn lowers DA uptake...
  12. ncbi request reprint Tolerance to the neurotoxic effects of methamphetamine in young rats
    Evan L Riddle
    University of Utah, Department of Pharmacology and Toxicology, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 435:181-5. 2002
    ..The methamphetamine biweekly pretreatment attenuated the hyperthermia caused by the neurotoxic methamphetamine regimen; a phenomenon that may have contributed to the neuroprotection...
  13. ncbi request reprint Persistence of tolerance to methamphetamine-induced monoamine deficits
    Jonathan P Danaceau
    Center for Human Toxicology, University of Utah, UT 84112, USA
    Eur J Pharmacol 559:46-54. 2007
    ....
  14. ncbi request reprint Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Addiction 102:44-8. 2007
    ..To review studies delineating the neurotoxic effects of methamphetamine on monoamine transport in dopaminergic neurons of the striatum and nucleus accumbens...
  15. pmc Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    Eur J Pharmacol 571:25-8. 2007
    ..These data represent the first report that amphetamine redistributes VMAT-2 protein. In addition, these data demonstrate that the trafficking of VMAT-2 after amphetamine or methylphenidate is selective for monoaminergic neurons...
  16. ncbi request reprint Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Pharmacol Exp Ther 323:738-45. 2007
    ....
  17. pmc Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Pharmacol Exp Ther 327:161-7. 2008
    ....
  18. pmc Differential regional effects of methamphetamine on dopamine transport
    Pei Wen Chu
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 590:105-10. 2008
    ....
  19. ncbi request reprint Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity
    J Paul Hansen
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Pharmacol Exp Ther 300:1093-100. 2002
    ..Taken together, these results reveal several differences between effects of MDMA and previously reported METH on DAT and VMAT-2; differences that may underlie the dissimilar neurotoxic profile of these agents...
  20. ncbi request reprint Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein
    Jannine G Truong
    University of Utah, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 504:27-32. 2004
    ..Taken together, these data demonstrate that dopamine D2 receptor subtype activation increases vesicular dopamine uptake. Implications of this phenomenon with regard to the treatment of Parkinson's disease will be discussed...
  21. ncbi request reprint Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Rm 201 84112, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 449:71-4. 2002
    ..These data suggest that psychostimulants acutely and differentially affect VMAT-2 subcellular localization...
  22. ncbi request reprint Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors
    Veronica Sandoval
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Neurosci 22:8705-10. 2002
    ..These observations suggest a role for DA in the MPD-induced redistribution of VMAT-2. The implications of this phenomenon will be discussed...
  23. ncbi request reprint Inhibitory effect of reserpine on dopamine transporter function
    Ryan R Metzger
    Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City 84112, USA
    Eur J Pharmacol 456:39-43. 2002
    ..Taken together, these data suggest that reserpine may transiently alter dopamine transporter function in a noncompetitive, indirect manner...
  24. ncbi request reprint Ceramide-induced alterations in dopamine transporter function
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, Room 201, 30 South 2000 East, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 458:31-6. 2003
    ..e., which presumably competes for uptake with 5-HT). Taken together, these results reveal that ceramide is a novel modulator of monoamine transporter function, and may alter the affinity of dopamine transporters for its primary substrate...
  25. ncbi request reprint Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits
    Veronica Sandoval
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Pharmacol Exp Ther 304:1181-7. 2003
    ..These findings not only provide insight into the neurotoxic effects of methamphetamine but also mechanisms underlying dopamine neurodegenerative disorders, including Parkinson's disease...
  26. ncbi request reprint Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors
    Yvette V Ugarte
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 472:165-71. 2003
    ..Unlike methamphetamine, the dopamine reuptake inhibitors, methylphenidate and cocaine, rapidly increased vesicular dopamine uptake. The implications of these phenomena are discussed...
  27. ncbi request reprint Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration
    Jannine G Truong
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 474:223-6. 2003
    ..The implications of this finding relevant to the treatment of neurodegenerative disorders are discussed...
  28. ncbi request reprint Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications
    Glen R Hanson
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    Ann N Y Acad Sci 1025:146-50. 2004
    ....
  29. ncbi request reprint The methamphetamine experience: a NIDA partnership
    Glen R Hanson
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Room 112, Salt Lake City, UT 84112, USA
    Neuropharmacology 47:92-100. 2004
    ....
  30. ncbi request reprint Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration
    Jannine G Truong
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 492:143-7. 2004
    ..This effect of apomorphine on vesicular dopamine uptake was blocked by pretreating with eticlopride, a dopamine D2 receptor antagonist. The implications of these findings relevant to the treatment of neurodegeneration are discussed...
  31. ncbi request reprint Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism
    Anthony J Baucum
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Neurosci 24:3436-43. 2004
    ..The implications of this phenomenon with regard to the neurotoxic potential of these stimulants are discussed...
  32. ncbi request reprint Age-dependent effects of methamphetamine on VMAT-2
    Kristi S Rau
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Room 201, Salt Lake City, UT 84112, USA
    Ann N Y Acad Sci 1074:154-9. 2006
    ....
  33. pmc Role of monoamine transporters in mediating psychostimulant effects
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    AAPS J 7:E847-51. 2005
    ....
  34. ncbi request reprint Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine
    Kamisha L Johnson-Davis
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112 9457, USA
    J Pharmacol Exp Ther 309:578-86. 2004
    ..In summary, these data are the first to demonstrate an association between the prevention of acute alterations in vesicular dopamine uptake and the development of tolerance to the neurotoxic effects of methamphetamine...
  35. pmc Mechanisms of methamphetamine-induced dopaminergic neurotoxicity
    Evan L Riddle
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    AAPS J 8:E413-8. 2006
    ..This review will describe the current understanding of how high-dose METH administration leads to the production of these toxic reactive species and consequent permanent dopaminergic deficits...
  36. ncbi request reprint The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits
    Trent J Volz
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
    J Neurochem 101:883-8. 2007
    ....
  37. ncbi request reprint The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity
    Kamisha L Johnson-Davis
    Department of Pharmacology and Toxicology, University of Utah, 20 South 2030 East, Room 490, Salt Lake City, UT 84112 9457, USA
    Eur J Pharmacol 482:151-4. 2003
    ..These data differ from previous findings thereby highlighting that different mechanisms contribute to the tolerance of the neurotoxic effects...
  38. ncbi request reprint Phencyclidine increases vesicular dopamine uptake
    Michael J Crosby
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 438:75-8. 2002
    ..These data demonstrate a heretofore unreported mechanism that may contribute to the ability of PCP to influence dopamine neuronal function and exert its pharmacological effects...

Research Grants21

  1. K02 Application
    ANNETTE FLECKENSTEIN; Fiscal Year: 2007
    This is a Career Development Award proposal for Dr. Annette Fleckenstein. She is an Associate Professor of Pharmacology and Toxicology at the University of Utah...
  2. Psychostimulants and Monoamine Transporters
    ANNETTE FLECKENSTEIN; Fiscal Year: 2009
    ....
  3. DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINES
    ANNETTE FLECKENSTEIN; Fiscal Year: 2009
    ..This, in turn, may enhance understanding of a variety of DAT-associated disorders ranging from stimulant abuse to neurodegenerative diseases such as Parkinson's disease. ..
  4. Psychostimulants and Monoamine Transporters
    ANNETTE FLECKENSTEIN; Fiscal Year: 2010
    ....
  5. DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINES
    ANNETTE FLECKENSTEIN; Fiscal Year: 2007
    ..This, in turn, may enhance understanding of a variety of DAT-associated disorders ranging from stimulant abuse to neurodegenerative diseases such as Parkinson's disease. ..
  6. Psychostimulants and Monoamine Transporters
    ANNETTE FLECKENSTEIN; Fiscal Year: 2007
    ..Finally, these studies will advance our understanding of a wide array of processes including those underlying addiction and those contributing to the development of DA neurodegenerative diseases. ..
  7. DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINES
    ANNETTE FLECKENSTEIN; Fiscal Year: 2004
    ..The mechanism and selectivity of this phenomenon will be studied. ..
  8. DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINES
    ANNETTE FLECKENSTEIN; Fiscal Year: 2010
    ..This, in turn, may enhance understanding of a variety of DAT-associated disorders ranging from stimulant abuse to neurodegenerative diseases such as Parkinson's disease. ..